PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
Top Cited Papers
Open Access
- 31 January 2011
- journal article
- Published by Springer Science and Business Media LLC in Oncogene
- Vol. 30 (22), 2547-2557
- https://doi.org/10.1038/onc.2010.626
Abstract
No abstract availableKeywords
This publication has 56 references indexed in Scilit:
- AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and ActivityCancer Cell, 2011
- Novel anticancer targets: revisiting ERBB2 and discovering ERBB3Nature Reviews Cancer, 2009
- Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast CancerJournal of Clinical Oncology, 2009
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancersNature Medicine, 2008
- A transforming mutation in the pleckstrin homology domain of AKT1 in cancerNature, 2007
- EGF–ERBB signalling: towards the systems levelNature Reviews Molecular Cell Biology, 2006
- A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in gliomaCancer Cell, 2006
- BRAF mutation predicts sensitivity to MEK inhibitionNature, 2005
- PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell, 2004
- Mutations of the BRAF gene in human cancerNature, 2002